Long-term facial improvement after repeated BoNT-A injections and mirror biofeedback exercises for chronic facial synkinesis: A case-series study

European Journal of Physical and Rehabilitation Medicine

Volumn 52, Issue 6, 2016, Pages 810-818

  Mandrini, Silvia ^a   Comelli, Mario ^a   Dall'Angelo, Anna ^a   Togni, Rossella ^a   Cecini, Miriam ^a   Pavese, Chiara ^a   Dalla Toffola, Elena ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Facial paralysis; Injections; Onabotulinumtoxina; Rehabilitation; Synkinesis, Biofeedback, psychology

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

BIOFEEDBACK; CONVALESCENCE; FACIAL PARALYSIS; FEMALE; HUMAN; KINESIOTHERAPY; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOPHYSIOLOGY; PROCEDURES; SYNKINESIS; TREATMENT OUTCOME;

BIOFEEDBACK, PSYCHOLOGY; BOTULINUM TOXINS, TYPE A; COMBINED MODALITY THERAPY; EXERCISE THERAPY; FACIAL PARALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; RECOVERY OF FUNCTION; SYNKINESIS; TREATMENT OUTCOME;

EID: 85007462390     PISSN: 19739087     EISSN: 19739095     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Moran CJ, Neely JG. Patterns of facial nerve synkinesis. Laryngoscope 1996;106:1491-6.
2. Beurskens CH, Oosterhof J, Nijhuis-van der Sanden MW. Frequency and location of synkineses in patients with peripheral facial nerve paresis. Otol Neurotol 2010;31:671-5.
3. Laskawi R, Damenz W, Roggenkämper P, Baetz A. Botulinum toxin treatment in patients with facial synkinesis. Eur Arch Otorhinolaryngol 1994;suppl:195-9.
4. Roggenkämper P, Laskawi R, Damenz W, Schröder M, Nußgens Z. Orbicular synkinesis after facial paralysis: treatment with botulinum toxin. Doc Ophthalmol 1994;86:395-402.
5. Laskawi R. The use of botulinum toxin in head and face medicine: an interdisciplinary field. Head Face Med 2008;4:5.
6. Husseman J, Mehta RP. Management of synkinesis. Facial Plast Surg 2008;24:242-9.
7. Dalla Toffola E, Furini F, Redaelli C, Prestifilippo E, Bejor M. Evaluation and treatment of synkinesis with botulinum toxin following facial nerve palsy. Disabil Rehabil 2010;32:1414-8.
8. Jost WH, Kohl A. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 2001;248:21-4.
9. Defazio G1, Abbruzzese G, Girlanda P, Vacca L, Currà A, De Salvia R, et al. Botulinum toxin A treatment for primary heifacial spasm: a 10-year multicenter study. Arch Neurol 2002;59:418-20.
10. Dressler D, Saberi FA, Barbosa ER. Botulinum toxin. Mechanisms of action. Arq Neuropsiquiatr 2005;63:180-5.
11. Ito H, Ito H, Nakano S, Kusaka H. Low-dose subcutaneous injection of botulinum toxin type A for facial synkinesis and hyperlacrimation. Acta Neurol Scand 2007;115:271-4.
12. Azuma T1, Nakamura K, Takahashi M, Ohyama S, Toda N, Iwasaki H, et al. Mirror biofeedback rehabilitation after administration of single-dose botulinum toxin for treatment of facial synkinesis. Otolaryngol Head Neck Surg 2012;146:40-5.
13. Czyz CN, Burns JA, Petrie TP, Watkins JR, Cahill KV, Foster A. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol 2013;156:173-177.e2.
14. Jitpimolmard S, Tiamkao S, Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 1998;64:751-7.
15. Dall'Angelo A, Mandrini S, Sala V, Pavese C, Carlisi E, Comelli M, et al. Platysma synkinesis in facial palsy and botulinum toxin type A. Laryngoscope 2014;124:2513-7.
16. Cecini M, Pavese C, Comelli M, Carlisi E, Sala V, Bejor M, at al. Quantitative Measurement of Evolution of Postparetic Ocular Synkinesis Treated with Botulinum Toxin Type A. Plast Reconstr Surg 2013;132:1255-64.
17. Nüssgens Z, Roggenkämper P. Long-term treatment of blepharospasm with botulinum toxin type A. Ger J Ophthalmol 1995;4:363-7.
18. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-Term Efficacy of Botulinum Toxin A in Treatment of Various Movement Disorders over a 10-Year Period. Mov Disord 2002;17:1288-93.
19. Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin a injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol 2014;42:254-61.
20. Ross B, Nedzelski JM, McLean JA. Efficacy of feedback training in long-standing facial nerve paralysis. Laryngoscope 1991;101:744-50.
21. Dalla Toffola E, Bossi D, Buonocore M, Montomoli C, Petrucci L, Alfonsi E. Usefulness of BFB/EMG in facial palsy rehabilitation. Disabil Rehabil 2005;27:809-15.
22. Lee JM, Choi KH, Lim BW, Kim MW, Kim J. Half-mirror biofeedback exercise in combination with three botulinum toxin A injections for long-lasting treatment of facial sequelae after facial paralysis. J Plast Reconstr Aesthet Surg 2015;68:71-8.
23. Pavese C, Tinelli C, Furini F, Abbamonte M, Giromini E, Sala V, et al. Validation of the Italian version of the Sunnybrook Facial Grading System. Neurol Sci 2013;34:457-63.
24. Fattah AY, Gurusinghe AD, Gavilan J, Hadlock TA, Marcus JR, Marres H, et al: Sir Charles Bell Society. Facial nerve grading instruments: systematic review of the literature and suggestion for uniformity. Plast and Reconstr Surg 2015;135:569-79.
25. Berg T, Jonsson L, Engström M. Agreement between the Sunnybrook, House-Brackmann, and Yanagihara facial nerve grading systems in Bell's palsy. Otol Neurotol 2004;25:1020-6.
26. Kanerva M, Poussa T, Pitkäranta A. Sunnybrook and House-Brackmann facial grading systems: intrarater repeatability and interrater agreement. Otolaryngol Head Neck Surg 2006;135:865-71.
27. Coulson SE, Croxson GR, Adams RD, O'Dwyer NJ. Reliability of the "Sydney," "Sunnybrook," and "House Brackmann" facial grading systems to assess voluntary movement and synkinesis after facial nerve paralysis. Otolaryngol Head Neck Surg 2005;132:543-9.
28. Choi KH, Rho SH, Lee JM, Jeon JH, Park SY, Kim J. Botulinum toxin injection of both sides of the face to treat post-paralytic facial synkinesis. J Plast Reconstr Aesthet Surg 2013;66:1058-63.
29. Stennert E. The autoparalytic syndrome - a leading symptom of postparetic facial function. Arch Otorhinolaryngol 1982;236:97-114.
30. Stennert E. Synkineses and the autoparalytic syndrome. In: Beurskens CHG, van Gelder RS, Heymans PG, Manni JJ, Nicolai J-PA, editors. The Facial Palsies. Utrecht: Lemma Publishers; 2005. p.117-33.
31. Sawyer AR, See M, Nduka C. Quantitative analysis of normal smile with 3D stereophotogrammetry - an aid to facial reanimation. J Plast Reconstr Aesthet Surg 2010;63:65-72.
32. Sessle BJ, Adachi K, Avivi-Arber L, Lee J, Nishiura H, Yao D, et al. Neuroplasticity of face primary motor cortex control of orofacial movements. Arch Oral Biol 2007;52:334-7.
33. Draganski B, May A. Training-induced structural changes in the adult human brain. Behav Brain Res 2008;192:137-42.
34. Klingner CM, Volk GF, Brodoehl S, Burmeister HP, Witte OW, Guntinas-Lichius O. Time course of cortical plasticity after facial nerve palsy: a single-case study. Neurorehabil Neural Repair 2012;26:197-203.
35. Múnera A, Cuestas DM, Troncoso J. Peripheral facial nerve lesions induce changes in the firing properties of primary motor cortex layer 5 pyramidal cells. Neuroscience 2012;223:140-51.